Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
What factors would push you to consider using IMRT vs opposed lateral fields for a T2N0 glottic SCC?
Would having supraglottic extension lead you to use IMRT?
Answer from: Radiation Oncologist at Academic Institution
I use IMRT for all. IMRT should not cause recurrence if done correctly.
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Academic Institution
A low lying larynx where parallel opposed lateral fields and anterior oblique fields are not feasible.
Sign In
or
Register
to read more
2585
2579
Related Questions
Is there a role for reirradiation for SCC oral tongue with high-risk features (i.e., PNI, close margins) following surgery?
What is your recommendation for patients who are on weight loss medications like GLP-1-based therapies while receiving chemoradiation for head and neck cancer?
How do you counsel patients regarding alcohol consumption following treatment of head and neck cancer?
What are your top takeaways in Head & Neck Cancers from ASCO 2025?
What is the role of radiation therapy for Kimura's disease of the parotid and neck?
What alternatives do you recommend for oral dexamethasone solution for HN cancer?
How would you approach a patient with synchronous HPV-mediated bilateral tonsil primary with ipsilateral lymph nodes who cannot receive chemotherapy?
What is the recommended treatment approach for stage III/IVA nasopharyngeal cancer that is p16 negative and EBV positive?
How do you manage a twice-recurrent mucinous adenocarcinoma of the lower eyelid with direct involvement of the lateral rectus muscle and lacrimal duct?
Would you recommend adjuvant radiation for a patient with head/neck merkel cell carcinoma following a pathologic complete response to neoadjuvant immunotherapy?